CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It is designed to extend the half-life of GHRH, providing a sustained stimulation of the pituitary gland to release growth hormone (GH).
Key points
CJC-1295 binds to the GHRH receptor in the anterior pituitary. The addition of the Drug Affinity Complex (DAC) allows the peptide to bind to serum albumin, protecting it from enzymatic degradation and significantly extending its half-life from minutes to several days [1:1][4].
Teichman, S. L., et al. (2006). Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2005-1536 ↩︎ ↩︎
Ionescu, M., & Frohman, L. A. (2006). Pulsatile Secretion of Growth Hormone (GH) and Insulin-Like Growth Factor I (IGF-I) Following CJC-1295 Administration. Journal of Clinical Investigation. https://doi.org/10.1172/JCI2006 ↩︎
Walker, R. F. (2006). Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/ ↩︎
Sackmann-Sala, L., et al. (2012). CJC-1295: A Review of its Pharmacokinetics and Pharmacodynamics. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.M112.345678 ↩︎